Patents Assigned to Graybug Vision, Inc.
  • Publication number: 20180326078
    Abstract: An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 15, 2018
    Applicant: Graybug Vision, Inc.
    Inventors: Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
  • Patent number: 10117950
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: November 6, 2018
    Assignee: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Patent number: 10111964
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 30, 2018
    Assignee: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Patent number: 10098965
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: October 16, 2018
    Assignee: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Patent number: 9956302
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: May 1, 2018
    Assignee: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Publication number: 20180110864
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 26, 2018
    Applicant: Graybug Vision, Inc.
    Inventors: Jeffrey R. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Publication number: 20180104350
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 19, 2018
    Applicant: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Publication number: 20180064823
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Application
    Filed: October 12, 2017
    Publication date: March 8, 2018
    Applicant: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Publication number: 20180036416
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 8, 2018
    Applicant: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Publication number: 20180028673
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Applicant: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Patent number: 9808531
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: November 7, 2017
    Assignee: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
  • Publication number: 20170135960
    Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.
    Type: Application
    Filed: November 11, 2016
    Publication date: May 18, 2017
    Applicant: GRAYBUG VISION, INC.
    Inventors: Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
  • Publication number: 20170080092
    Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 23, 2017
    Applicant: Graybug Vision, Inc.
    Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang